Skip to main contentSkip to navigationSkip to search

Recruitment completed in uPAR-PET study in brain cancer

June 30, 2022


Copenhagen, Denmark, 30 June 2022 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today that the investigator-initiated phase II study using uPAR-PET in brain cancer has now completed the inclusion of patients

The investigator-initiated trial testing 68Ga-NOTA-AE105 uPAR-PET/MR in patients with gliomas (most common primary brain cancers) aimed to collect data on 30 patients out of a total of 35 patients recruited to the trial. This number has now been reached and the first data analysis can begin according to the primary investigator.

The trial, being carried out at Rigshospitalet in Copenhagen, is designed to investigate the diagnostic performance of uPAR-PET in brain cancer.

“We are extremely pleased that the investigator-initiated phase II study using the uTRACE® technology in brain cancer has now included all patients, having overcome early challenges in recruitment due to the COVID-19 pandemic.” Said Curasight CEO Ulrich Krasilnikoff. “ We look forward to seeing first data from this study in brain cancer, as we believe it will also give us important insight into the best way forward of using the uPAR-targeting radionuclide therapy uTREAT® in brain cancer patients, in particular the most aggressive high-grade gliomas.”

First data from the study is expected to be published during H2 2022.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60


Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel theranostic platform with Positron Emissions Tomography (PET) imaging and Radionuclide Therapy targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis, risk stratification and therapy in multiple cancer types.